Sutro Biopharma, Inc. (STRO) Misses Q1 EPS by 6c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q1 EPS of ($0.91), $0.06 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $17.39 million versus the consensus estimate of $9 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance